The comment in the recent post about Johnson & Johnson’s approach to Ortho Evra litigation — specifically, the suggestion that the company was “the anti-Merck” in terms of its legal strategy because of its willingness to settle — got my wheels turning about the different ways that corporations respond to the legal fallout of drugs that create liability. So here is a comparison of what we know about three companies — Merck, Johnson & Johnson, and Bausch & Lomb — and how they are responding to issues related to Vioxx, Ortho Evra, and ReNu with MoistureLoc, respectively.
Address
